Results 201 to 210 of about 27,407 (265)

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source

Case Report: Euglycemic ketoacidosis in a non-diabetic patient: a rare adverse effect of SGLT2 inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Prasad S, Sharma S, Shetty R, Singh S, Parmar V, Shivaprasad C, Dhaduk V.   +6 more
europepmc   +1 more source

Characterization of AF Recurrence and Substrate Health by Electrographic Flow (EGF) Consistency in EGF Mapping

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Electrographic flow (EGF) mapping is an FDA 510(k)‐cleared method for visualizing atrial activation wavefronts in atrial fibrillation (AF). Its clinical efficacy in detecting AF sources was demonstrated in the FLOW‐AF randomized controlled trial, and the underlying machine learning strategy used to develop and refine EGF source ...
Steven Castellano, Marloes Jansen, Lucas V. A. Boersma, Marisa van der Graaf, Melissa H. Kong, Kostiantyn Ahapov, Philip Haeusser, Moritoshi Funasako, John D. Hummel, Wilber W. Su   +9 more
wiley   +1 more source

Characteristics and Outcomes of IgA Nephropathy Patients With SGLT2 Inhibitor-Induced Polycythemia. [PDF]

Cureus
Furuto Y, Namikawa A, Sato D, Shibuya Y.
europepmc   +1 more source

Time‐Dependent Accrual of Cardiorenal Benefit With SGLT2 Inhibitors in Chronic Kidney Disease: A Reconstructed Individual Patient Data Meta‐Analysis of Randomized Trials

Diabetes, Obesity and Metabolism, EarlyView.
Shotaro Yoshida, Mashiro Iwatsubo, Takahiro Nakamura, Makiko Oda, Yusuke Sakamaki   +4 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

SGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction. [PDF]

Medicina (Kaunas)
Keskin B, Hakgor A, Khidolda Y, Dursun A, Akhundova A, Savur U, Olgun FE, Onder O, Gul YG, Cakal B, Demir B, Gunes HM, Karaca IO, Guler E, Boztosun B.   +14 more
europepmc   +1 more source

Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice

Journal of Diabetes Investigation, EarlyView.
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan, Tian‐Rong Li, Jing‐Jing Yang, Xiao‐Lu Li, Wen‐Qin Li, Jin‐Wen Yu   +5 more
wiley   +1 more source

Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection. [PDF]

Diabetologia
Jansz TT, Young KG, Hopkins R, McGovern AP, Shields BM, Hattersley AT, Jones AG, Pearson ER, Bingham C, Oram RA, Dennis JM, MASTERMIND Consortium.   +11 more
europepmc   +1 more source